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Summary
Intrinsic estrogenicities of the selective estrogen receptor modulators (SERMs) toremifene 60 mg daily or 200 mg
daily and tamoxifen 20 mg daily (TOR60, TOR200 and TAM20) were compared in a randomized clinical study in
postmenopausal women with advanced breast cancer. The study was open label in three parallel groups. Variables
for analysis were serum follicle stimulating hormone (FSH), luteinizing hormone (LH), sex hormone binding
globulin (SHBG), estradiol (E2), antithrombin III (AT III), aspartate aminotransferase (ASAT) and vaginal cytol-
ogy. Clinical efficacy and safety have been reported earlier. A total of 648 patients were randomized (221 to
TOR60, 212 to TOR200 and 215 to TAM20). Sera were available for the analysis from 148, 165 and 156 and
for vaginal cytology from 98, 93 and 86 patients, respectively. All treatment regimens showed tissue-specific and
dose-dependent estrogen agonist effect. In the primary measure of in vivo estrogenicity, effect on hypothalamus–
pituitary-axis, all three treatment regimens decreased serum FSH (p < 0.001). TOR200 was more potent than
the two other treatments (p < 0.05), but surprisingly, TAM20 was more estrogenic than TOR60 (p < 0.001). As
could be expected in postmenopausal women, the treatments had no effect on mean serum E2 concentrations
and decrease of serum LH was similar to that of FSH. Estrogenic effect on the liver was seen as dose-dependent
increase of SHBG with statistically significant differences between the treatment groups (p < 0.001). Trends of
transient ASAT elevations in TOR200 group (p = 0.07) and in all treatment groups AT III decrease (p = 0.1) were
seen in the beginning of the treatment. TOR60 or TAM20 did not have an effect on mean ASAT values, and AT
III decreased in TAM20 group more than in the two other groups (p = 0.1 compared to TOR60 and p < 0.05
compared to TOR200). Estrogenic effects on vaginal superficial cells were higher in TOR60 and TOR200 groups
when compared to TAM20 (p < 0.05). Toremifene and tamoxifen had tissue-specific and partially dose-dependent
estrogenic effects in hypothalamus–pituitary-axis, in the liver and in the vaginal epithelium of postmenopausal
women. In some tissues tamoxifen 20 may be more estrogenic than toremifene 60 mg/day.
Introduction
Triphenylethylene antiestrogens, which have more re-
cently been designated as selective estrogen receptor
modulators (SERMs), are widely used to treat all
stages of breast cancer [5, 13, 29]. Clinical trials to
study breast cancer preventive effects of SERMs at
high-risk patients are ongoing, although the first re-
sults are controversial [9, 30, 36]. The triphenyl-
ethylene derivative toremifene acts mainly as an
antiestrogen in humans [21, 22] and, like tamoxifen,
another tripehenylethylene SERM, it binds to intracel-
lular estrogen receptor (ER).
The effect of SERMs depend on the target tissue.
Typically, in breast they inhibit cell proliferation,
whereas in liver, they stimulate protein synthesis,
for example, sex hormone binding globulin (SHBG)
[22, 23]. In the central nervous system, toremifene
inhibits TRH-stimulated prolactin secretion [40].
The estrogenic or antiestrogenic activity of SERMs is
also species specific. Toremifene has clear estrogenic
effect in mouse and dog while in rats and humans it is
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predominantly antiestrogenic. In postmenopausal
women toremifene doses 20, 40 or 60 mg daily in-
duce dose-dependent estrogenic action by decreasing
LH and FSH in and increasing SHBG concentrations
in serum [6]. Toremifene 10 mg daily has no clear
antiestrogenic activity on vaginal cytology in post-
menopausal women with concomitant estradiol (E2)
[18]. However, doses of 20, 40 and 80 mg daily exert
marked antiestrogenic effects, which are not different
from each other or from tamoxifen 20 mg/day.
In clinical studies, toremifene doses from 20 to
300 mg/day have been studied for the treatment of
advanced breast cancer in postmenopausal women.
Twenty milligram daily produces fewer responses than
60 mg daily with similar times to progression [6, 14,
26, 32, 41]. Higher dose (240 mg/day) may increase
the response rate slightly more [16]. In early trials
[27] tamoxifen 40 mg/day was more effective than
20 mg, but in a comparative study [3] no difference
in efficacy of the two doses was seen. In postmeno-
pausal women with advanced breast cancer toremifene
60 mg/day has been equally effective as tamoxifen 20
or 40 mg/day [11, 15, 33, 34] and again the higher dose
of toremifene 200 or 240 mg show slightly increased
response rate [12].
Three years or longer of adjuvant tamoxifen treat-
ment has been shown to be more effective in prevent-
ing breast cancer recurrences than less than 2 years
[5]. However, more than 5 years of treatment is appar-
ently not superior to 5 years [8]. Tamoxifen treatment
has been associated with increased incidence of sub-
sequent endometrial cancer [2, 4, 7, 10, 24, 31, 36].
The observed carcinogenicity is considered to be due
to estrogenic stimulation on the endometrium. Some
endometrial cancers cases have been reported follow-
ing toremifene administration, but in early results from
prospective randomized and epidemiological studies,
no increase of endometrial cancer incidence has been
observed [28, 31]. The aim of the present study was
to investigate estrogenic effects of the standard SERM
doses, toremifene 60 mg and tamoxifen 20 mg daily,
and compare them to a high dose, toremifene 200 mg
daily, which was only used in clinical trials.
Patients and methods
Study design
The clinical trial from which samples were obtained
was a multicenter, randomized, open label study
comparing TOR60 and TOR200 to TAM20. The
clinical efficacy and safety results of the study have
been published earlier [15]. The variables for the
present analysis were serum follicle stimulating hor-
mone (FSH), luteinizing hormone (LH), SHBG, E2,
aspartate aminotransferase (ASAT), antithrombin III
(AT III) and vaginal superficial cell count.
The study was conducted to comply with the WHO
criteria and the principles of the Helsinki declaration.
It was approved by ethical committees in each study
site and signed informed consents were given by the
patients before randomization.
Patient selection
Eligibility included postmenopausal women, at least
1 year since their last menstruation or serum FSH
>50 mIU/ml or perimenopausal women >45 years
of age and with menopausal symptoms. Previously
untreated patients with advanced ER positive (ER
concentration ≥10 fmol/mg protein), or ER unknown
breast cancer were eligible for the study. ECOG scale
performance status needed to be 0–2. Previous ra-
diotherapy and tamoxifen for advanced breast cancer
were allowed, provided that tamoxifen had not lasted
for more than 14 days. Patients with previous adjuvant
tamoxifen or chemotherapy were eligible, provided
that at least 12 months had elapsed since the dis-
continuation of tamoxifen. Patients with severe renal
(serum bilirubin >2 mg/dl) insufficiency, advanced
liver disease (SGOT >100 IU/l) brain metastases, his-
tory of thromboembolic disease or concomitant active
second malignancy were excluded.
Randomization and treatment regimen
Six hundred and forty-eight patients with advanced
breast cancer were enrolled at 129 sites in six coun-
tries and were randomized to one of three arms (one
toremifene 60 mg tablet daily, one toremifene 200 mg
tablet daily or two tamoxifen 10 mg tablets daily in
TOR60, in TOR200 and in TAM20, respectively). No
dose modifications were allowed and the treatments
were scheduled to continue to breast cancer progres-
sion, intolerable toxicity serious intercurrent illness
or patient non-compliance (<80% of planned drug
taken). Other cancer treatment was not allowed during
the study. Accrual began 11 November 1988 and was
completed 31 August 1991.
Patient evaluation and response criteria
Within 3 weeks prior to the treatment, the patients un-
derwent medical history, physical examination, blood
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chemistry, hemoglobin, leukocyte and platelet counts,
performance status and tumor evaluation. Mandatory
blood samples were to be drawn during the control
visits, sera were separated and stored at −20◦C for
analysis. The assessments and sampling were repeated
at 8-week intervals with the methods used at baseline.
The biochemical variables of interest were changes in
nonfasting serum FSH, LH, E2 and in SHBG assessed
by standard immunometric methods at laboratories
collaborating with each clinical site. Liver function
tests in terms of changes in serum ASAT and AT III
concentrations were assessed for tolerability. All pa-
tients who had baseline and at least one subsequent
serum assessment available, that is, at least 8 weeks
treatment were included into the primary efficacy anal-
ysis. Each individual value obtained was compared
to the laboratory reference range of the laboratory.
Gynecological examination including vaginal cytol-
ogy, that is, superficial cell counts was performed at
baseline, at week 8 and off treatment.
Statistics
Sample size for the clinical trial [15] was estimated
to show equivalence in response rates among TOR60,
TOR200 and TAM20. Each pair of treatment arms was
compared using an overall type-one error rate (α) of
0.05. In this study, treatment effect on the hormonal
variables were assessed with analysis of covariance
for repeated measurements, that is, between factor
treatment and within factor time. The values at the
start of the treatment were considered as baseline.
The primary analysis was based on baseline assess-
ments and all available data obtained thereafter. If the
patients baseline value was missing, the patient was
excluded from the analyses. Primary analysis was sup-
ported by the so-called last point analysis, in which
only baseline and the last available data point of each
variable were analyzed. Rank sum test was used for
the analysis of vaginal cytology. Descriptive statistics
were used to characterize the patient population. All
data were independently verified for correctness and
subjected to both manual and computerized checks for




Between 11 November 1988 and 31 August 1991,
648 patients (221 in TOR60, 212 in TOR200 and
215 in TAM20) were randomized. A total of 327
patients (165 in TOR60, 156 in TOR200 and 148 in
TAM20) received at least 8 weeks treatment and were
eligible for the present analysis of hormonal variables.
The main reason for nonevaluability was breast cancer
progression at or before 8 weeks control excluding
patient from further analysis. The patient characteris-
tics in the present study population were not different
from the whole population in the clinical study [15].
The pretreatment characteristics of the patients are
evenly balanced among the treatment arms as shown
in Table 1.
FSH
Serum mean FSH concentrations declined in all treat-
ment groups during the first 10 months of treatment
(Figure 1) reaching premenopausal values in about
8 weeks. The mean FSH concentrations were differ-
ent among the treatment groups. The lowest concen-
tration was seen in TOR200 group when compared
to TOR60 (p < 0.05) or TAM20 groups (p < 0.001).
Lower mean concentrations were seen in TAM20 than
in TOR60 group (p < 0.001). Analysis of last avail-
able data point compared to baseline confirmed the
observed fall of serum FSH. In this analysis, the differ-
ence between TOR60 and TAM20 was not significant
(p = 0.15).
LH
The mean serum LH concentrations declined in all
treatment groups during the first 2 months of treat-
ment (Figure 2). Although the mean baseline concen-
trations were not clearly within the postmenopausal
range, the decline in the treatment groups were sim-
ilar to those seen in FSH. The mean concentrations
of LH were different among the treatment groups
(p < 0.01). Again, the lowest concentrations were
seen in TOR200 group and the differences when com-
pared to TAM20 (p < 0.001) and TOR60 (p = 0.07)
were similar to those seen in FSH. As in FSH, lower
mean LH concentrations were seen in TAM20 group
than in TOR60 group (p < 0.07). Last point analysis
confirmed the LH decline during the treatments, but
again, the difference between TOR60 and TAM20 was
not significant (p = 0.5).
E2
Mean serum E2 concentrations increased (≥30
pcg/ml) in TAM20 and TOR200 groups after 10
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Table 1. The baseline characteristics of postmenopausal patients with advanced breast cancer
in toremifene 60 mg/day (TOR60), toremifene 200 mg/day (TOR240) and tamoxifen 20 mg/day
(TAM20) treatment groups
Characteristic Treatment
Tamoxifen 20 mg Toremifene 60 mg Toremifene 200 mg
(n = 148) (n = 165) (n = 156)
Age (years)
Mean ± std dev. 61.4 ± 10.960 63.5 ± 10.277 62.6 ± 10.360
Range 35–82 43–88 41–85
Weight
Mean ± std dev. 71.1 ± 16.823 68.9 ± 17.021 69.4 ± 15.462
Range 43–124.3 33.6–124.3 35–123
Height
Mean ± std dev. 161.7 ± 7.469 161.0 ± 6.591 160.4 ± 6.659
Range 145–188 149.8–190.5 137–185.4
Menopausal status: (n = 147) (n = 164) (n = 156)
Postmenopausal with
absence of menses 1 year 124 (84.4%) 142 (86.5%) 135 (86.5%)
Perimenopausal with
irregular menses/hot flash 8 (5.4%) 6 (3.7%) 6 (3.9%)
Surgically menopausal
after prior ooph. 15 (10.2%) 16 (9.8%) 15 (9.6%)
 
   
Figure 1. Mean FSH concentrations (IU/l) in the serum of postmen-
opausal breast cancer patients receiving tamoxifen 20 mg (TAM20,
solid line), toremifene 60 mg (TOR60, dotted line) or toremifene
200 mg (TOR200, dashed line) daily for at least 8 weeks.
months of treatment (p < 0.05, for time and treat-
ment interaction), although overall mean concen-
trations were not statistically different (p = 0.09)
 
 
Figure 2. Mean LH concentrations (IU/l) in the serum of postmen-
opausal breast cancer patients receiving tamoxifen 20 mg (TAM20,
solid line), toremifene 60 mg (TOR60, dotted line) or toremifene
200 mg (TOR200, dashed line) daily for at least 8 weeks.
among the treatment groups (Figure 3). Likewise
no significant increases were observed in last point
analysis.
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Figure 3. Mean E2 concentrations (pcg/ml) in the serum of
postmenopausal breast cancer patients receiving tamoxifen 20 mg
(TAM20, solid line), toremifene 60 mg (TOR60, dotted line) or
toremifene 200 mg (TOR200, dashed line) daily for at least 8 weeks.
SHBG
Dose-dependent increase of SHBG concentration was
seen in all treatment groups during the first 8 weeks of
treatment (Figure 4). The mean concentrations were
different among the treatment groups (p < 0.001), so
that the concentration in theTOR200 group was higher
when compared to TAM20 (p < 0.001) or TOR60
(p < 0.01). In the contrary to FSH and LH, SHBG
concentrations increased more in the TOR60 than in
 
Figure 4. Mean SHBG concentrations in the serum of postmeno-
pausal breast cancer patients receiving tamoxifen 20 mg (TAM20,
solid line), toremifene 60 mg (TOR60, dotted line) or toremifene




Figure 5. Mean ASAT concentrations (IU/l) in the serum of
postmenopausal breast cancer patients receiving tamoxifen 20 mg
(TAM20, solid line), toremifene 60 mg (TOR60, dotted line) or
toremifene 200 mg (TOR200, dashed line) daily for at least 8 weeks.
the TAM20 group. Last point analysis confirmed this
finding.
ASAT
During treatment, no increases of mean ASAT values
were observed in TAM20 or TOR60 groups. In the
TOR200 group mean ASAT concentrations increased
during weeks 8–24 (p < 0.01, for time and treat-
ment interaction), but the mean concentrations were
not different among the treatment groups (p = 0.07,
Figure 5). Last point analysis indicated significant
overall difference among the groups (p < 0.05). This
was due to the increase in the TOR200 group, which
was more than in TOR60 (p < 0.05) or TAM20
(p < 0.01). TOR60 and TAM20 groups did not dif-
fer from each other (p = 0.49). ASAT increases
>100 IU/l were observed in 11, 22 and 4 patients in
the TOR60, in the TOR200 and in the TAM20 groups,
respectively [33]. The difference between TAM20 and
TOR200 was statistically significant (p < 0.05). How-
ever, in no case the treatments were discontinued due
to the elevated liver function tests.
AT III
AT III was assessed most often at baseline and at
week 8. Serum samples of 116, 115 and 98 patients
in TOR60, TOR200 and TAM20 were available for
the analysis. AT III decreased 8.8% in TOR60, 8.4%
in TOR200 and 13.8% in TAM20 groups. In the last
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point analysis, more reduction was seen in the TAM20
group than in TOR60 (p = 0.09) or in TOR200
(p < 0.05), but the decrease over the treatment groups
was not statistically significant (p = 0.10).
Vaginal cytology
A total of 277 patients 86 in TAM20, 98 in TOR60
and 93 in TOR200 had baseline and 8 weeks super-
ficial cell counts available for assessment. The mean
counts at baseline were 3.3, 4.0 and 4.5, and in all
treatment groups the counts increased by week 8 up
to 10.0, 15.7, and 15.8, respectively. The counts were
higher in TOR60 and TOR200 groups when compared
to TAM20 (p < 0.05).
Clinical safety
Overall all treatments were well tolerated. A total of
21 patients discontinued the treatment due to clinical
toxicity (3 in TAM20, 6 in TOR60 and 12 in TOR200).
The most frequent single reasons for withdrawal were
hypercalcemia and CNS symptoms in four patients
in both groups. Two patients were removed from the
TOR200 group due to multiple liver function abnor-
malities, which were resolved after discontinuation of
the drug.
Discussion
SERMs are used for the treatment of breast cancer
mainly to prevent breast cancer growth by their anti-
estrogenic activity. However, some of the estrogenic
actions of the SERMs are also beneficial, such as pre-
vention of osteoporosis or lowering LDL cholesterol.
Endometrium stimulating effects, increased incidence
of thromboembolic complications or even stimulation
of breast cancer cell growth [20, 43] are unwanted
effects.
In this study, we have found that the estrogenicity
of TOR60, TOR200 and TAM20 in postmenopausal
women were similar but not identical. The SERMs
were estrogenic in both the pituitary and liver, doc-
umented by decreased serum FSH and LH and in-
creased SHBG, respectively (Table 2). As well as in
the vaginal epithelium as shown by the increase of
superficial cell counts. Premenopausal levels of FSH
and LH were reached within 8 weeks and maximal es-
trogenic effect in the liver at 16 weeks. In the TAM20
and TOR200 groups the FSH and LH concentrations
Table 2. Relative decreases (−/− −/− − −), increases (+/+ +/+
+ +) or no change (NC) in FSH, LH, E2, SHBG, ASAT, AT
III concentrations and vaginal superficial cell counts in postmen-
opausal breast cancer patients receiving tamoxifen 20 mg (TAM20),
toremifene 60 mg (TOR60) or toremifene 200 mg (TOR200) daily
for at least 8 weeks
Treatment
Tamoxifen Toremifene Toremifene
20 mg 60 mg 200 mg
(n = 148) (n = 165) (n = 156)
FSH − − − − − −
LH − − − − − −
SHBG + ++ + + +
E2 + NC +
ASAT NC NC +
AT III − NC NC
Vaginal + ++ + +
superficial
cell count
decreased further after reaching the expected steady
state level of the study drugs at 4 weeks [1]. Estrogens
increase SHBG concentrations [42] and, as expected,
serum SHBG correlated positively with the dose and
serum concentration of the SERMS. However, the es-
trogenic effects of the two SERMs were not directly
dose-dependent in the pituitary. Again, most estro-
genic activity was shown by toremifene 200 mg, but
tamoxifen 20 mg was more estrogenic than toremifene
60 mg. This is consistent with the preclinical finding
by di Salle et al. [39], who found toremifene less estro-
genic than tamoxifen within equipotent antiestrogenic
doses in the rat. In postmenopausal breast cancer pa-
tients toremifene 40–60 mg had similar bone sparing
[25, 38] and serum LDL decreasing/HDL increasing
effect [19, 37], that is, estrogenic effects.
Toremifene 200 mg induced more clinically non-
significant abnormalities in the liver function tests,
which is consistent with the higher SHBG synthesis
induction capacity of the regimen. No difference be-
tween toremifene 60 mg and tamoxifen 20 mg was
seen in this respect. Treatment regimens slightly de-
creased serum AT III concentrations. TAM20 tended
to decrease AT III more than the two other regi-
mens but the fall over the treatment groups was not
statistically significant. Tamoxifen has observed to
increase incidence of thromboembolic complications
seen during long term treatment [9]. In a recently
reported study, fewer thromboembolic complica-
tions were observed in postmenopausal breast cancer
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patients treated with long term toremifene 40 mg daily
treatment when compared to tamoxifen 20 mg daily
[17]. This observation may be due to lower estrogenic
potential and lower thrombosis risk.
Earlier studies with toremifene in doses ranging
from 20 to 80 mg daily has been shown to be anti-
estrogenic [18] in vaginal cytology in healthy post-
menopausal volunteers when given after transdermal
E2. No dose response was seen and the effect was
no different than with tamoxifen from 10 to 20 mg
daily. In this study, when given without exogenous
estrogen, all treatments were estrogenic in the vaginal
epithelium. No difference between the two toremifene
regimens were seen and both showed more estrogen
agonist activity than tamoxifen. In clinical studies no
difference in vaginal bleeding or discharge has been
seen between toremifene 60–240 and tamoxifen 20–40
[11, 12, 15, 34].
The treatments were well tolerated and discon-
tinuation due to toxicity was rare. The toxicity was
most often related to the antiestrogenic effects of the
drugs such as menopausal like symptoms with no
differences among the groups. More patients with
transiently elevated liver transaminases were seen on
high dose toremifene [15] indicating that this may be
a dose effect that was supported by preclinical find-
ings [23]. However, at the lower dose of toremifene,
no such dose-dependent liver stimulation was seen
[6, 15, 17].
The present results agree with the earlier studies
confirming that toremifene, among other hormonal
agents, is an effective drug for the treatment of ad-
vanced breast cancer in postmenopausal women. Ac-
cording to phase I studies toremifene 20 mg/day is the
lowest dose with antiestrogenic effect [18]. No differ-
ence in efficacy has been seen between tamoxifen 20
and 40 mg daily doses [3], suggesting that therapeutic
window for triphenylethylene derivatives is wide and
that increasing the dose does not necessarily improve
the effect. TOR60 has been shown to be as effective
as tamoxifen 20–40 mg/day [34] and the recent find-
ings [17] demonstrate that 40 mg/day is as effective as
tamoxifen in the adjuvant setting.
Available clinical data suggest that the maximal
breast cancer growth inhibiting effect of triphen-
ylethylenes is reached early during dose escalation and
that higher total doses, possibly with added estrogenic
effect, increase toxicity. This study demonstrated that
although biochemical differences were induced among
the three treatment groups, no clinical differences
were observed in the therapeutic trial [15]. In these
patients with metastatic breast cancer, response rates
and times to progression were similar for TOR60,
TOR200 and TAM20. Toremifene 40–60 mg daily is
safe and effective treatment for postmenopausal wom-
en with ER positive or ER unknown breast cancer. The
lower estrogenic potential and clinically equivalent
efficacy with tamoxifen make toremifene an inter-
esting alternative for long term treatment of breast
cancer.
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